Cytek Biosciences, Inc. CTKB
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About CTKB
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Cytek Biosciences, Inc. is a U.S.-based life sciences technology company focused on advanced cell analysis instruments and related consumables for biomedical research and clinical applications. The company operates primarily within the flow cytometry and cell analysis markets, serving academic research institutions, pharmaceutical and biotechnology companies, clinical laboratories, and government research organizations. Cytek is best known for its full spectrum flow cytometry technology, which captures and analyzes the complete emission spectra of fluorochromes to improve multiplexing capability and cellular analysis performance compared with conventional flow cytometry systems.
Cytek’s principal revenue drivers include sales of flow cytometry instruments, recurring consumables and reagents, software solutions, and service contracts. Its flagship platforms include the Aurora and Northern Lights systems, alongside imaging and sample preparation technologies acquired through strategic transactions. The company traces its origins to 2006 and expanded significantly following the commercialization of spectral flow cytometry platforms and its 2021 public listing on Nasdaq under the ticker CTKB. Cytek has positioned itself as a differentiated provider in high-parameter cell analysis through proprietary optical designs, integrated software, and a growing installed base that supports recurring revenue generation.
Business Operations
Cytek generates revenue through instrument sales, consumables, service agreements, and software offerings tied to its flow cytometry ecosystem. Its primary operating activities revolve around the development, manufacture, and commercialization of spectral flow cytometry systems and associated products. Key business platforms include the Aurora, Northern Lights, and Amnis product lines, with the latter expanding the company’s capabilities into imaging flow cytometry following the acquisition of selected assets from Luminex Corporation. Consumables and reagents provide recurring revenue streams tied to instrument utilization across research and clinical settings.
The company operates internationally through direct sales operations and distributor networks across North America, Europe, and Asia-Pacific. Cytek maintains manufacturing and operational capabilities in the United States while supporting customers globally through field service infrastructure and channel partners. Strategic relationships with research institutions, biotechnology firms, and clinical laboratories support product adoption and workflow integration. Cytek also maintains intellectual property related to optical detection systems, spectral unmixing algorithms, and high-parameter cellular analysis technologies.
Strategic Position & Investments
Cytek’s strategic direction has centered on expanding its installed base of spectral flow cytometry systems, increasing recurring consumables revenue, and broadening its technology portfolio through acquisitions and product innovation. The company has invested in enhancing automation, imaging capabilities, and workflow integration for high-dimensional cell analysis. A notable strategic transaction was the acquisition of certain imaging and flow cytometry assets associated with Amnis and Guava technologies from Luminex Corporation, which expanded Cytek’s addressable market and product offerings.
The company has also pursued international expansion, particularly in China and broader Asia-Pacific markets, where demand for advanced life sciences instrumentation has grown alongside increased biomedical research investment. Cytek continues to invest in software-enabled analytics, spectral cytometry advancements, and clinical research applications, including immunology, oncology, and cell therapy development. Its competitive positioning is supported by proprietary spectral technology, lower system complexity relative to some high-end competitors, and an emphasis on scalable multiplexed analysis.
Geographic Footprint
Cytek is headquartered in Fremont, California, and maintains a global commercial presence spanning the Americas, Europe, and Asia-Pacific regions. The company serves customers in more than 100 countries through a combination of direct operations and third-party distribution partnerships. Its largest markets include the United States, China, and several major European research hubs where flow cytometry adoption is well established.
Internationally, Cytek has expanded commercial and support infrastructure to strengthen penetration in academic research centers, pharmaceutical companies, and clinical laboratories. The company’s operational footprint includes regional sales offices, technical support capabilities, and distributor relationships designed to support instrument deployment and recurring consumable demand. Public filings and investor materials indicate that international markets account for a substantial portion of total revenue, with Asia-Pacific representing an important growth region.
Leadership & Governance
Cytek’s leadership team combines experience in life sciences instrumentation, diagnostics, manufacturing, and commercial operations. The company was co-founded by flow cytometry technology specialists and has maintained a strategic emphasis on innovation-driven growth and expansion within high-parameter cellular analysis markets. Governance oversight is provided through a board structure aligned with U.S. public company standards following its Nasdaq listing.
Key executives include:
- Wenbin Jiang – Co-Founder, Chief Executive Officer
- Ming Yan – President
- Patrick Balthrop – Chairperson of the Board
- Ajit Singh – Board Member
- Paulina Licznerski – Chief Financial Officer
Management has consistently emphasized expanding the installed instrument base, increasing recurring revenue through consumables and services, and broadening Cytek’s technological capabilities through internal development and acquisitions. Information regarding executive roles and governance structure has been verified through SEC filings, company investor materials, and public corporate disclosures.